Latest 10-K annual reports

GP-Act III Acquisition Corp., a blank check company, filed its 2025 Annual Report on Form 10-K, detailing its financial position, ongoing search for a business combination, and associated risks.

Seafarer Exploration Corp. reports significant operating losses, a substantial working capital deficit, and auditor doubts about its ability to continue as a going concern for the year ended December 31, 2025.

DBV Technologies reports positive Phase 3 VITESSE results for its Viaskin Peanut patch in children aged 4-7, secures significant financing, and outlines accelerated regulatory pathways for both toddler and child populations in the U.S.

Abercrombie & Fitch Co. reported a 6% increase in net sales for Fiscal 2025, reaching $5.27 billion, but saw a decline in operating income and net income compared to the prior year, alongside a strategic review of its APAC business.

Dermata Therapeutics shifts focus from prescription drugs to direct-to-consumer and B2B skincare products, reporting continued losses and a going concern warning.

Oramed Pharmaceuticals Inc. reports a significant net income swing in 2025, driven by strategic investment revaluations and a new path for its oral insulin program.

CV Sciences reported a 12.2% drop in net product sales for 2025 and a 'substantial doubt' about its ability to continue as a going concern, despite improved gross margins and reduced operating losses.

Buda Juice, Inc. reports an 11.8% increase in net sales to $12.6 million for 2025, maintaining profitability despite higher produce costs and IPO-related expenses, as it transitions to a public company.

Wrap Technologies reports increased gross revenue and strategic expansion into new public safety and defense markets, despite continued operating losses in 2025.

Newsmax Inc. reported a 10.7% increase in total revenue to $189.3 million for 2025, driven by broadcasting growth, but saw its net loss widen to $99.5 million amidst significant legal settlements and increased operating costs.

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported net income for 2025 but faces substantial doubt about its ability to continue as a going concern due to its business combination deadline.

Lightstone Value Plus REIT V, Inc. reported a 4.3% increase in its estimated Net Asset Value per Share to $16.56 as of September 30, 2025, alongside a net income of $5.1 million for the year, driven by asset sales and refinancing activities.

Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for 2025, narrowing from $165.9 million in 2024, as it strategically restructured to prioritize its lead oncology candidate, azenosertib, and extend its cash runway into late 2027.

Cantor Equity Partners IV, a blank check company, reported a net income of $6.13 million for 2025, primarily from Trust Account interest, as it continues its search for a business combination in target sectors like financial services and technology.

CapsoVision reported increased revenue but widening net losses and a going concern warning, signaling significant financial and operational challenges despite product development efforts.

Quoin Pharmaceuticals reports significant clinical progress for its lead Netherton Syndrome drug QRX003, including positive Phase 2 data and FDA openness to pivotal study design, despite ongoing substantial net losses and a going concern warning.

Worksport Ltd. reports significant revenue growth and successful capital raises in 2025, despite continued net losses and a going concern warning from auditors.

Rein Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, leading to an indefinite pause in LTI-01 and preclinical programs.

Chaince Digital Holdings Inc. reported a strategic pivot to financial services and advisory businesses in 2025, discontinuing its Filecoin mining operations, alongside significant revenue growth in its core segment but an increased net loss.

Interlink Electronics reported a reduced net loss of $1.615 million in 2025, driven by strong growth in industrial and automotive markets and strategic financial restructuring.

Ulta Beauty's fiscal 2025 saw net sales rise 9.7% to $12.4 billion and comparable sales grow 5.4%, but net income decreased by $47.6 million due to higher operating expenses and interest costs.

Vivani Medical, Inc. reported a net loss of $26.6 million in 2025 while advancing its NanoPortal GLP-1 implant programs and securing significant capital.

Inhibikase Therapeutics initiated a global Phase 3 clinical study for its lead product candidate, IKT-001 for Pulmonary Arterial Hypertension, while reporting increased net losses and significant capital raises in 2025.

LB Pharmaceuticals Inc. reports significant progress in its clinical pipeline, with lead candidate LB-102 entering Phase 3 for acute schizophrenia and Phase 2 for bipolar depression, alongside a recent $100 million capital raise.

SANUWAVE Health, Inc. announced a significant financial turnaround in its 2025 annual report, achieving net income and substantial revenue growth following a debt refinancing and prior period restatements.

Microbot Medical Inc. reports FDA clearance for its LIBERTY Endovascular Robotic Surgical System and initiates limited market release, while continuing to incur significant operating losses and requiring additional funding.

Identiv, Inc. reported a net loss of $18.0 million in 2025, a significant improvement from the prior year's continuing operations loss, as it fully transitioned to an IoT-focused business after divesting its Physical Security segment.

INNOVATE Corp. reported a significant net loss in 2025 and faces substantial doubt about its ability to continue as a going concern, prompting strategic asset sales and debt refinancing efforts.

enVVeno Medical Corporation received a non-approvable letter from the FDA for its VenoValve, prompting a strategic pivot to its next-generation enVVe System, a non-surgical venous valve, with pivotal trials expected to begin in 2026.

SKYX Platforms Corp.'s 2025 annual report details revenue growth driven by smart products and e-commerce, alongside continued operating losses and significant capital needs.